RNA Therapeutics Conference

, London , United Kingdom

Innovations in technologies and applications of RNA-based medicine

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.

The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.

Join us in February 2021, as our 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry, upcoming regulatory updates and industry implications.

Benefits of Attending:

  • Explore in industry insights into how mRNA is being used to combat COVID-19
  • Engage in case studies exploring the growing therapeutic potential of RNA for rare diseases
  • Delve into future trends in AI application for optimal RNA therapeutics
  • Hear regulatory outlooks of the RNA landscape, clinical trials and looking ahead

Who should attend:

  • Research & Development Directors/Managers/Scientists
  • Heads of Clinical Development
  • Heads of Pre-Clinical Development
  • Head of RNA Biology
  • Head of RNA Formulation and Drug Delivery
  • Head of Pre-clinical R&D
  • Head of New Modalities
  • Head of Discovery
  • Senior Scientists
  • Chief Scientific Officers
  • Chief Medical Officers

Focus day on RNA Interference - 12th February 2021

As the industry of RNA therapeutics advances this year's focus day will explore the growing potential of RNA interference. The focus day will present sessions that explore the evolving approaches to RNAi including: antifibrotic microRNA-based therapeutics for the treatment of Alport syndrome, self-deliverable RNAi and an exploration into how siRNA can be modified for self-delivery, and targeted delivery of nucleic acid therapeutics. Furthermore, this year's focus day will be highlighting the emerging trends and future outlook of RNAi in the Pharmaceutical industry.

Featured Speakers

  • Andre Müller-York, Senior Medical Affairs Director , Sarepta Therapeutics Germany GmbH
  • Arpan Desai, Team Leader, Astrazeneca
  • Cristina Reschke, Lecturer, Royal College of Surgeons in Ireland
  • David Evans, Chief Scientific Officer, Sirnaomics, Inc
  • Dong Yu, Fellow, Senior Director, and Head, GSK Vaccines
  • Dong-Ki Lee, CEO, OilX Pharmaceuticals
  • Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
  • Jennifer Pluim, Vice President Medical Afffairs, ProQR
  • Kirsty Wydenbach, Senior Medical Assessor / Deputy Unit Manager , MHRA
  • Maria Luisa Pineda, CEO and Co-founder, Envisagenics
  • Michael Mulqueen, VP Business Development, eTheRNA Immunotherapies
  • Ruchi Shah, Senior Research Engineer, Eli Lilly and Company
  • Shalini Andersson, Chief Scientist New Therapeutic Modalitiesand Head of Oligonucleotide Discovery, AstraZeneca
  • Thomas Thum, Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School
  • Troels Koch, CEO & Founder, Aqiventa

Please fill in your name and email to receive the Conference Agenda of this event.

Venue

Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK

Event details
Organizer : SMi
Event type : Conference
Reference : ASDE-22552